U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07501208) titled 'Dendritic Cell Vaccine to Prevent COVID-19' on Dec. 14, 2020.
Brief Summary: This is an adaptive Phase I trial of a vaccine consisting of autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein, with or without GM-CSF, to prevent COVID-19 in adults.
Study Start Date: Dec. 07, 2020
Study Type: INTERVENTIONAL
Condition:
COVID-19
Intervention:
BIOLOGICAL: AV-COVID-19
Autologous dendritic cells previously loaded ex vivo with SARS-CoV-2 spike protein
Recruitment Status: WITHDRAWN
Sponsor: Ina-Respond
Published by HT Digital Content Services with permission from Health Daily Digest....